tirzepatide weight loss en español Flyer Brochure Template GLP-1 Handout Weight Loss Injection Info Sheet Medspa Canva Editable Wellness Printable Tirzepatide Injections for Medical Weight

The FDA prescribing information includes a boxed warning for risk of thyroid C-cell tumors and contraindication in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)

Think of it like a factory running on a sputtering generator

Unlike some medications that require gradual dose reduction, tirzepatide can typically be stopped abruptly without a formal tapering schedule

Semaglutide 2.4 mg clinical outcomes in patients with obesity or overweight in a real-world setting: A 6-month retrospective study in the United States (SCOPE)

packaging details may vary by supplier

Purpose-built for physicians Tirzepatide led to greater real-world weight loss than semaglutide for adults with obesity Key takeaways: Adults with overweight or obesity using tirzepatide lost more weight than those using semaglutide